

SenzaGen changes its market maker to Carnegie

Lund, November 29, 2023

As a result of Carnegie Investment Bank's acquisition of business areas from Erik Penser Bank, SenzaGen has changed its market maker to Carnegie. The intention is to continue promoting liquidity in the SenzaGen stock.

In the role of market maker Carnegie undertakes to continuously provide bid and ask quotations in accordance with the requirements for liquidity providers set out by Nasdaq Stockholm. The purpose is to improve the liquidity of the share and reduce the spread between the buying and selling price. The assignment begins on November 30, 2023.

Contacts

Peter Nählstedt, President and CEO, SenzaGen AB Email: peter.nahlstedt@senzagen.com | Mobile: +46 700 23 44 31

Tina Dackemark Lawesson, VP Marketing & Communications Email: <u>tina.lawesson@senzagen.com</u> | Mobile: +46 708 20 29 44

About us

SenzaGen is a corporate group that aims to be a leader in *in vitro* science and testing, driving the transition from animal testing to methods better suited to reflect human biology. The Company provides high-performance, non-animal test methods and innovation and consulting services based on state-of-the-art technology. Non-animal methods are more effective, more accurate and less expensive than traditional animal-based methods while also helping to reduce the number of laboratory animals. The Company has a growth strategy centered around continued commercialization of its proprietary GARD® and VitroScreen ORA® test platforms, expansion of its test portfolio and evaluation of acquisition opportunities of profitable and growing companies with complementary offerings. SenzaGen has its headquarters and GLP-certified laboratory in Lund, Sweden and subsidiaries in the US and Italy. For more information, please visit: www.senzagen.com.

SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA). FNCA Sweden AB is the company's Certified Adviser.

Attachments

SenzaGen changes its market maker to Carnegie